OCA
BBOT

Octagon Capital Advisors’s BridgeBio Oncology BBOT Stock Holding History

Octagon Capital Advisors’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-719,000
Closed -$6.44M – 33
2026
Q1 		$6.44M Sell
719,000
-324,110
-31% -$3.48M 0.71% 24
2025
Q4 		$13.1M Hold
1,043,110
– – 1.59% 21
2025
Q3 		$12.1M Buy
1,043,110
+793,110
+317% +$8.26M 1.83% 18
2025
Q2 		$2.66M Hold
250,000
– – 0.58% 26
2025
Q1 		$2.83M Hold
250,000
– – 0.55% 35
2024
Q4 		$2.63M Hold
250,000
– – 0.43% 30
2024
Q3 		$2.61M Hold
250,000
– – 0.41% 32
2024
Q2 		$2.56M Hold
250,000
– – 0.4% 35
2024
Q1 		$2.59M Buy
+250,000
New +$2.59M 0.31% 51

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Octagon Capital Advisors's BBOT Position: Q2 2026 in Review

Octagon Capital Advisors sold out of BridgeBio Oncology (BBOT) in Q2 2026, closing a stake of 719,000 shares — an estimated $6.44M sold.

Octagon Capital Advisors first reported a position in BBOT in Q1 2024 and held it in 9 quarters. The position peaked at $13.1M in Q4 2025. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Octagon Capital Advisors reported no remaining BridgeBio Oncology position as of Q2 2026 after selling out during the quarter.
  • Octagon Capital Advisors sold 719,000 BridgeBio Oncology shares in Q2 2026, an estimated $6.44M.
  • Octagon Capital Advisors first reported a position in BridgeBio Oncology in Q1 2024 and held it in 9 quarters.
  • Octagon Capital Advisors's BridgeBio Oncology position peaked at $13.1M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.